Note: This document contains side effect information about ublituximab. Some dosage forms listed on this page may not apply to the brand name Briumvi.
Applies to ublituximab: intravenous solution.
Serious side effects of Briumvi
Along with its needed effects, ublituximab (the active ingredient contained in Briumvi) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking ublituximab:
More common
- Body aches or pain
- chest pain or tightness
- chills
- cough
- cough producing mucus
- diarrhea
- dizziness
- dryness or soreness of the throat
- ear congestion
- facial swelling
- fever or chills
- general feeling of discomfort or illness
- headache
- hoarseness
- joint pain
- loss of voice
- muscle aches and pains
- nausea or vomiting
- pain or tenderness around the eyes and cheekbones
- skin rash
- sneezing
- stuffy or runny nose
- sweating
- tender, swollen glands in the neck
- trouble breathing
- trouble in swallowing
- trouble sleeping
- unusual tiredness or weakness
- voice changes
- vomiting
Incidence not known
- Back pain
- blurred vision
- confusion
- dark urine
- drowsiness
- light-colored stools
- seizures
- upper right abdominal or stomach pain
- yellow eyes and skin
Other side effects of Briumvi
Some side effects of ublituximab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common
- Pain in the arms or legs
For Healthcare Professionals
Applies to ublituximab: intravenous solution.
General
The most common adverse reactions, with a frequency of 10% or greater, were infusion reactions and upper respiratory tract infections. The most common cause that led to treatment discontinuation was infection.
Immunologic
Common (1% to 10%): Herpes virus-associated infections[Ref]
Musculoskeletal
Common (1% to 10%): Pain in extremity[Ref]
Other
-The most reported infusion reaction symptoms, with a frequency of 5% or greater, include pyrexia, chills, headache, and influenza-like illness.
-Serious infusion reactions occurred in 0.6% of patients.[Ref]
Very common (10% or more): Infusion reactions (48%), decreased neutrophil levels (15%)
Common (1% to 10%): Fatigue
Frequency not reported: Decreased immunoglobulins[Ref]
Psychiatric
Common (1% to 10%): Insomnia[Ref]
Respiratory
-Upper respiratory tract infections include nasopharyngitis, upper respiratory tract infection, respiratory tract infection (viral), pharyngitis, rhinitis, sinusitis, acute sinusitis, tonsillitis, laryngitis, chronic sinusitis, viral pharyngitis, viral rhinitis, viral upper respiratory tract infection, chronic tonsillitis, pharyngitis streptococcal, bacterial sinusitis, and bacterial tonsillitis.
-Lower respiratory tract infections include bronchitis, pneumonia, tracheitis, tracheobronchitis, COVID-19 pneumonia, bacterial bronchitis, and viral pneumonia.[Ref]
Very common (10% or more): Upper respiratory tract infections (45%)
Common (1% to 10%): Lower respiratory tract infections[Ref]
